GLP-1 Peptides Explained: How Semaglutide and Tirzepatide Are Reshaping Metabolic Medicine

The global burden of obesity and type 2 diabetes has demanded a pharmacological breakthrough for decades. What we have in GLP-1 receptor agonists is arguably the most consequential development in metabolic medicine since metformin entered clinical use in the 1950s. Semaglutide and tirzepatide — the two agents that have come to define this moment — are not simply weight loss medications. They are precision metabolic tools that interact with some of the body's most fundamental hormonal systems, producing effects that reach far beyond glycemic control or the number on a scale.

This guide covers the biology behind these peptides, how each one works, what the clinical evidence actually demonstrates, who qualifies for therapy, what to realistically expect, and where the science is heading. Whether you are actively evaluating GLP-1 therapy or simply trying to make sense of the conversation, what follows is grounded in the clinical evidence — not the marketing.

In this guide:

• What are GLP-1 peptides?
• How semaglutide works
• Tirzepatide vs semaglutide: the clinical evidence
• Who qualifies for GLP-1 therapy?
• What to realistically expect
• Side effects and safety
• Metabolic monitoring on GLP-1 therapy
• What happens when you stop?
• The future of GLP-1 and metabolic peptides
• FAQ
• Meto's perspective

What Are GLP-1 Peptides? The Biology Behind the Breakthrough 

GLP-1 as a naturally occurring incretin hormone

Glucagon-like peptide-1 (GLP-1) is a hormone secreted by L-cells lining the small intestine and colon in response to nutrient intake. It belongs to a class of hormones called incretins — gut-derived signals that amplify the pancreas's response to rising blood glucose. When you eat, GLP-1 is released into circulation within minutes, triggering insulin secretion in a glucose-dependent manner, suppressing glucagon, and signaling the brain that the gut has received nutrients.

What distinguishes GLP-1 from most hormones is the breadth of its receptor distribution. GLP-1 receptors are expressed not just in the pancreas but across the hypothalamus, brainstem, heart, kidneys, liver, and vasculature. This multi-organ signaling network is precisely what makes GLP-1 receptor agonists such versatile clinical tools — and why their documented effects extend well beyond blood sugar management into cardiovascular risk, liver disease, kidney protection, and neurological function.

The half-life problem — and the pharmaceutical solution

The therapeutic challenge with endogenous GLP-1 is its brevity. The enzyme dipeptidyl peptidase-4 (DPP-4) degrades native GLP-1 within approximately two minutes of secretion. This rapid clearance makes native GLP-1 pharmacologically useless — any infusion would require continuous administration at impractical doses.

The pharmaceutical engineering task, then, was to design a molecule with GLP-1 receptor affinity durable enough for clinical application. Semaglutide solved this by attaching a C18 fatty diacid chain to a modified GLP-1 backbone, enabling the drug to bind reversibly to albumin in the bloodstream and evade DPP-4 degradation. The result: a half-life of approximately seven days, enabling once-weekly subcutaneous injection (Drucker DJ, Nat Rev Drug Discov, 2022). Tirzepatide introduced a further architectural departure, adding a second incretin receptor target — a distinction covered in detail in the next section.

How Semaglutide Works: The Mechanism of a GLP-1 Receptor Agonist 

Semaglutide — the active molecule in both Ozempic and Wegovy — shares 94% structural homology with native human GLP-1. Its clinical effects run through four interlocking pathways:

Glucose-dependent insulin secretion. Semaglutide binds GLP-1 receptors on pancreatic beta cells, amplifying insulin output in proportion to circulating glucose. Because this stimulation is glucose-dependent, the risk of hypoglycemia is substantially lower than with sulfonylureas or exogenous insulin — the drug augments the body's existing glucose-sensing mechanism rather than overriding it.

Glucagon suppression. GLP-1 receptors on pancreatic alpha cells mediate glucagon release. Semaglutide suppresses glucagon secretion, reducing the liver's glucose output during fasting. Elevated fasting glucagon is a principal driver of overnight hyperglycemia in type 2 diabetes, and this suppression is one of the drug's most clinically meaningful effects on HbA1c.

Gastric emptying delay. Semaglutide slows the transit of food from the stomach to the small intestine, blunting post-meal glucose excursions and extending satiety. This mechanism also underlies much of the early-treatment nausea — a physiological consequence of altered gastric motility, not a toxicological event.

Central appetite suppression. GLP-1 receptors in the hypothalamus and hindbrain — specifically areas governing hunger and satiety — respond to semaglutide by downregulating appetite drive and amplifying satiety signaling. Neuroimaging studies have confirmed that semaglutide attenuates activation in reward-related brain regions in response to food cues, suggesting effects on hedonic eating behavior alongside homeostatic hunger regulation (van Bloemendaal L et al., Diabetes Obes Metab, 2015). Patients frequently describe not eating less through willpower, but simply feeling full earlier and thinking about food less.

Ozempic versus Wegovy: same molecule, different clinical purposes

The frequent confusion between Ozempic and Wegovy is understandable — they contain the same active compound at different doses for different indications. Ozempic (0.5mg, 1mg, or 2mg weekly) is approved for type 2 diabetes management and cardiovascular risk reduction in adults with T2D and established disease. Wegovy (2.4mg weekly) is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. This distinction matters for prescribing criteria, insurance coverage, and clinical monitoring approach.

Tirzepatide vs Semaglutide: What the Clinical Evidence Actually Shows 

What makes tirzepatide mechanistically distinct

Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) co-activates two distinct incretin receptors: GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor). GIP is the other major gut-derived incretin hormone, secreted by K-cells of the upper small intestine. The physiological role of GIPR agonism in the context of obesity had been debated for years — early research suggested it might promote fat storage. However, the clinical reality of dual agonism has consistently contradicted that concern. The leading hypothesis is that GIPR and GLP-1R co-activation produces synergistic effects on adipose tissue lipolysis and central appetite regulation that neither pathway generates independently (Finan B et al., Sci Transl Med, 2013).

Head-to-head data: the SURMOUNT-5 trial

For years, the comparison between tirzepatide and semaglutide relied on cross-trial analysis — methodologically problematic because of differences in trial populations, endpoints, and follow-up duration. The SURMOUNT-5 trial, published in The Lancet in 2025, resolved this with a direct randomized comparison. Over 72 weeks, tirzepatide (10mg or 15mg weekly) produced approximately 20.2% mean body weight reduction compared to 13.7% with semaglutide 2.4mg — a difference representing roughly 47% greater weight loss with the dual agonist. A significantly larger proportion of tirzepatide-treated patients achieved ≥25% body weight reduction, a threshold previously accessible primarily through bariatric surgery (Garvey WT et al., Lancet, 2025).

For type 2 diabetes, HbA1c reductions with tirzepatide in the SURPASS trial family ranged from 1.87 to 2.07 percentage points at higher doses; comparable semaglutide data from the SUSTAIN trials demonstrate reductions of approximately 1.5 to 1.8 percentage points in similar populations.

Side effect comparison

Both agents share a predominantly GI side effect profile. SURMOUNT-5 showed nausea and vomiting slightly more common with tirzepatide, while constipation was reported more frequently with semaglutide. Discontinuation rates due to adverse events were comparable between groups, underscoring that tolerability — managed with proper dose titration — is roughly equivalent.

The clinical bottom line: tirzepatide produces greater absolute weight loss than semaglutide at maximum doses. For glycemic control in T2D, the difference is meaningful but less dramatic. For patients whose primary goal is cardiovascular risk reduction with proven outcomes data, semaglutide's SELECT trial evidence currently gives it an edge until tirzepatide's cardiovascular data matures.

Who Qualifies for GLP-1 Therapy?

FDA-approved indications

GLP-1 receptor agonists are currently approved across three primary clinical indications:

Type 2 diabetes management. All major GLP-1 agents — semaglutide, tirzepatide, liraglutide, dulaglutide — carry approval for glycemic management in adults with T2D.

Chronic weight management. Semaglutide (Wegovy) and tirzepatide (Zepbound) are both indicated for adults with a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

Cardiovascular risk reduction. Ozempic (semaglutide 1mg or 2mg) carries approval to reduce the risk of major adverse cardiovascular events in adults with T2D and established cardiovascular disease. Following the SELECT trial, semaglutide 2.4mg (Wegovy) now also carries cardiovascular risk-reduction labeling in adults with obesity and established CVD, without a diabetes diagnosis — a landmark regulatory expansion (Lincoff AM et al., NEJM, 2023).

Who should not use GLP-1 medications

Contraindications include:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2)
• Personal history of acute pancreatitis
• Active or severe gallbladder disease without treatment
• Pregnancy — GLP-1 medications should be discontinued well before attempting conception
• Severe renal impairment requires individual clinical assessment

The prescribing pathway

GLP-1 medications are prescription agents. They can be initiated through primary care, endocrinology, internal medicine, or metabolic medicine specialists — and increasingly through telehealth platforms. The critical variable is not the channel through which prescribing occurs, but whether it is accompanied by proper baseline evaluation and structured monitoring. A prescription written without pre-treatment labs and a follow-up plan is incomplete clinical practice.

For a detailed breakdown of what laboratory work is required before starting, see Meto's clinical guide: Lab Tests to Get Before Starting GLP-1 Therapy.

What to Realistically Expect: Weight Loss, Timelines, and Metabolic Outcomes 

Weight loss trajectories from trial data

GLP-1 therapy does not produce rapid results, and that is by pharmacological design. Clinical trial data show a consistent pattern: modest initial response in weeks 4–8, a steeper trajectory from months 2–6 as the therapeutic dose is established, and a plateau or near-plateau by weeks 60–72. This is not failure — it is normal metabolic adaptation. Patients who expect dramatic early loss frequently discontinue before reaching any meaningful therapeutic dose.

The STEP 1 trial demonstrated 14.9% mean body weight reduction with semaglutide 2.4mg at 68 weeks versus 2.4% with placebo in adults without diabetes (Wilding JPH et al., NEJM, 2021). SURMOUNT-1 showed tirzepatide achieving 15.0–22.5% body weight reduction depending on dose (5mg, 10mg, or 15mg weekly) at 72 weeks (Jastreboff AM et al., NEJM, 2022).

Metabolic benefits beyond weight

Weight reduction is the headline, but the cardiometabolic benefit profile is broader:

• Blood pressure reductions of 3–6 mmHg (systolic) are consistently reported across trials
• Meaningful improvements in fasting triglycerides and LDL-cholesterol
• Significant reductions in liver fat content, with emerging evidence for histological improvement in MAFLD
• The SELECT trial demonstrated a 20% relative risk reduction in major cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) with semaglutide in adults with obesity and established CVD — without a diabetes diagnosis

Non-responders

Approximately 10–15% of patients achieve less than 5% body weight reduction on GLP-1 therapy. Poor response does not indicate individual failure. It is often a signal that additional diagnostic evaluation — including assessment of insulin resistance severity, cortisol dynamics, thyroid function, and genetic factors — is warranted. Dose optimization and adjunct lifestyle intervention should be exhausted before concluding a patient is a true non-responder.

Dose titration: the most clinically underestimated variable

Both semaglutide and tirzepatide are initiated at sub-therapeutic doses and titrated upward over months. This protocol is essential — rushing it substantially increases GI side effects and early discontinuation. The full therapeutic dose of semaglutide (2.4mg) is typically not reached until week 16–20. For tirzepatide (10–15mg), a similar titration timeline applies. Most treatment failures in the first 4–8 weeks are failures of titration management, not failures of the medication.

For a month-by-month breakdown of what to expect on semaglutide, Meto's clinical timeline is a useful reference: Wegovy Timeline: What to Expect Month by Month.

Side Effects and Safety: Separating Clinical Evidence from Social Media Noise

Common GI effects

Nausea is the most reported adverse effect across all GLP-1 trials — occurring in 40–50% of patients at some point during treatment. It is tied to gastric emptying delay and is predominantly transient: most pronounced during the first weeks of each dose escalation, and substantially attenuated by months 2–3 in the majority of patients. Practical management strategies include eating smaller portions, reducing high-fat foods during early titration, and communicating with a prescriber about slowing the dose escalation schedule if needed.

Vomiting, diarrhea, and constipation occur at lower frequencies and are generally self-limiting. Persistent or severe GI symptoms warrant clinical review.

Rare but serious risks

Pancreatitis: GLP-1 receptor agonists carry a class warning for acute pancreatitis. Absolute risk elevation in large-scale trials has been modest and not statistically significant in most analyses, but patients with prior pancreatitis or active gallstone disease require a careful risk-benefit discussion before initiating therapy.

Gallbladder disease: Rapid weight loss through any mechanism increases bile lithogenicity. Cholelithiasis and cholecystitis occur at modestly elevated rates in GLP-1-treated patients compared to placebo.

Medullary thyroid carcinoma: The FDA black-box warning reflects rodent data showing dose-dependent thyroid C-cell hyperplasia. Human pharmacovigilance studies to date have not confirmed elevated MTC incidence, but the contraindication for individuals with MTC or MEN2 history remains firm.

Acute kidney injury: Severe vomiting and inadequate fluid intake can precipitate pre-renal AKI, particularly in patients with pre-existing renal impairment or those taking concomitant diuretics or NSAIDs. Hydration guidance is a necessary part of GLP-1 counseling.

"Ozempic face" and lean mass loss

The colloquial "Ozempic face" — facial hollowing during rapid weight loss — is a body composition phenomenon, not a drug-specific dermatological effect. Of greater clinical concern is lean mass loss. Data from multiple trials suggest approximately 25–40% of total weight lost on GLP-1 therapy is lean mass, broadly consistent with other caloric-restriction interventions. Mitigating this requires protein intake of at minimum 1.2g/kg body weight daily and structured resistance training during the treatment course. GLP-1 therapy without nutritional and exercise guidance is incomplete clinical management.

For a deeper look at what laboratory testing can reveal about organ-level risks — liver enzyme elevations, kidney function, and lipase — before symptoms appear, see GLP-1 Side Effects: What Lab Tests Can Catch Early.

GLP-1 Therapy and Metabolic Monitoring: What to Track and Why 

The single most significant gap in real-world GLP-1 prescribing is not eligibility — it is monitoring. A substantial proportion of patients receive prescriptions without baseline laboratory evaluation or a structured follow-up plan. Clinically, this is inadequate.

Baseline evaluation before starting

A responsible pre-treatment workup includes:

• HbA1c and fasting glucose — to establish glycemic baseline and identify undiagnosed prediabetes or diabetes
• Fasting insulin (with HOMA-IR) — to quantify insulin resistance severity. See Meto's clinical explainer: Fasting Insulin Test: What It Tells You and Why It Matters
• Full lipid panel — LDL, HDL, triglycerides, and non-HDL cholesterol
• Liver enzymes (ALT, AST, GGT) — baseline hepatic assessment, relevant given GLP-1's significant effects on liver fat metabolism
• Kidney function (eGFR, creatinine, BUN) — baseline renal status and contraindication screening
• TSH — thyroid function baseline
• Lipase — pancreatic enzyme baseline, especially with any pancreatitis risk factors

Ongoing monitoring schedule

At a minimum, liver enzymes, kidney function, HbA1c, lipid panel, and lipase should be rechecked at 3 months and 6 months. Blood pressure and body weight should be assessed at every clinical contact. Body composition monitoring — using bioelectrical impedance or DEXA — adds clinically meaningful data about the ratio of fat loss to lean mass loss, which is not captured by the scale alone.

The monitoring burden here is not excessive — it reflects the basic standard of care for any chronic pharmacotherapy. Providers who prescribe GLP-1 agents without establishing this structure are not following the medication safely.

Meto's comprehensive guide to the 10 key biomarkers that matter on GLP-1 therapy covers the what, when, and why in clinical depth: 10 Biomarkers to Track on GLP-1 Medications.

What Happens When You Stop GLP-1 Therapy? 

The weight regain data

The STEP 1 extension trial remains one of the most important — and most clinically sobering — datasets in this space. Participants who lost an average of 15% body weight during the 68-week semaglutide trial regained approximately two-thirds of that weight within one year of treatment withdrawal. Cardiometabolic markers — blood pressure, lipids, HbA1c — tracked the weight regain and largely reversed toward baseline (Wilding JPH et al., Diabetes Obes Metab, 2022).

This pattern is not a drug failure. It is a predictable biological consequence of removing pharmacological compensation from a system that remains dysregulated.

Why this happens — and how to frame it clinically

Obesity involves chronic dysregulation of hormonal weight-regulatory systems, including GLP-1 secretion itself. In many patients with obesity, endogenous GLP-1 secretion is impaired — producing less satiety signal after meals than in metabolically healthy individuals. GLP-1 receptor agonists pharmacologically compensate for this deficit. When the compensation is removed, the underlying dysregulation reasserts.

This reframe matters for patient counseling. The question is not "will I need this medication forever?" but "what does long-term metabolic management look like for my specific physiology?" Some patients successfully transition off GLP-1 therapy after establishing durable behavioral changes and achieving significant improvement in the metabolic conditions that drove obesity. Many will require ongoing pharmacological support, in the same way that hypertension or hypothyroidism require continuous management.

Emerging discontinuation strategies

Dose reduction rather than abrupt discontinuation, maintenance-phase dosing at lower doses, structured lifestyle bridging during drug holidays, and combination with insulin sensitizers or metformin are all being actively studied and implemented. The evidence base for formal discontinuation protocols remains limited — this is an active clinical research area.

The Future of GLP-1 and Metabolic Peptides 

Oral semaglutide

Rybelsus — oral semaglutide — is already approved for type 2 diabetes management. Its bioavailability challenges are real: approximately 1% absorption, requiring ingestion with a very small amount of water (≤120mL) in a fasted state, with no food or other medications for 30 minutes. For obesity indications, oral semaglutide formulations with enhanced delivery systems are in clinical trials. If bioavailability limitations can be meaningfully addressed, oral GLP-1 agonism would substantially expand access and adherence.

Triple agonism: retatrutide

Retatrutide adds glucagon receptor agonism to the GLP-1/GIP combination, creating a triple incretin agonist. The rationale for glucagon co-activation is its capacity to increase energy expenditure and hepatic fat mobilization — effects that complement the appetite suppression and insulin-sensitizing properties of the other two pathways. Phase 2 data published in NEJM showed weight loss of up to 24.2% at 48 weeks — exceeding tirzepatide's 72-week results in a shorter timeframe (Jastreboff AM et al., NEJM, 2023). Phase 3 trials are ongoing.

GLP-1 beyond metabolic disease

Perhaps the most significant development in GLP-1 research is the accumulation of benefit signals outside traditional metabolic indications:

• Cardiovascular disease — confirmed in SELECT (semaglutide) with 20% relative risk reduction in major cardiovascular events
• Liver disease (MAFLD/NASH) — Phase 3 trials for semaglutide demonstrating histological liver improvement; liver disease may become a standalone indication
• Obstructive sleep apnea — the SURMOUNT-OSA trial showed tirzepatide reduced the Apnea-Hypopnea Index (AHI) by approximately 55–63% versus placebo, with a dedicated FDA approval pathway now established
• Neurological conditions — observational data suggests reduced dementia incidence in patients on GLP-1 therapy; randomized Alzheimer's disease trials with semaglutide (EVOKE trials) are ongoing
• Addiction and substance use — early trial data and patient-reported outcomes suggest reduced alcohol cravings and compulsive behavior on GLP-1 therapy; dopaminergic pathway modulation is the leading mechanistic hypothesis
• PCOS — GLP-1 receptor agonists are an increasingly recognized option for the metabolic phenotype of PCOS, with demonstrated improvements in insulin resistance, androgen levels, and menstrual regularity. Meto's clinical team has covered this intersection in depth, including the emerging evidence for GLP-1 use in PCOS patients (explore PCOS care at Meto)

Frequently Asked Questions

Is semaglutide a peptide or a drug?

Semaglutide is both. It is a synthetic peptide — a modified chain of amino acids designed to mimic and sustain the activity of the naturally occurring GLP-1 hormone. It is also an FDA-approved pharmaceutical drug. The two categories are not mutually exclusive.

Can GLP-1 medications be taken without a diabetes diagnosis?

Yes. Both semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management in adults with obesity or overweight with a related comorbidity, regardless of diabetes status. Cardiovascular risk reduction labeling for semaglutide in non-diabetic adults with obesity and established CVD was added following the SELECT trial.

Are compounded semaglutide and tirzepatide safe?

Compounded versions — produced by pharmacies during brand-name shortages — bypass the quality-control standards applied to FDA-approved formulations. As the FDA resolved shortage designations for semaglutide in 2025, compounding restrictions tightened significantly. Patients using or considering compounded agents should do so only under direct physician oversight and with clear understanding of the regulatory landscape and quality variability.

How does GLP-1 therapy differ from older weight loss medications?

Older agents (phentermine, orlistat, topiramate) primarily modulated appetite through central stimulant mechanisms or inhibited fat absorption — with modest efficacy and significant tolerability concerns. GLP-1 receptor agonists work through a physiological hormonal mechanism with substantially larger absolute effect sizes and, for semaglutide, proven cardiovascular benefit. They represent a qualitatively different pharmacological category.

Can GLP-1 drugs affect fertility or be used during pregnancy?

GLP-1 receptor agonists should be discontinued before attempting conception and are contraindicated throughout pregnancy. The effect on fertility is less established; however, significant weight loss through any mechanism can restore ovulatory function in women with obesity-related anovulation or PCOS, so contraception should be addressed during treatment planning.

What is the difference between GLP-1 and GIP?

Both are incretin hormones released by the gut following food intake. GLP-1 — secreted by L-cells — primarily drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and suppresses central appetite. GIP — secreted by K-cells of the upper small intestine — also augments insulin secretion and has pronounced effects on adipose tissue metabolism. Tirzepatide co-activates both receptors, producing synergistic metabolic effects that appear to exceed what either pathway generates in isolation.

Meto's Perspective: Why Monitoring Is the Missing Variable in GLP-1 Care 

At Meto, we see GLP-1 therapy the way we approach metabolic health broadly: the prescription is the beginning of care, not the conclusion of it.

The clinical reality we encounter regularly is that patients arrive on semaglutide or tirzepatide without a pre-treatment metabolic baseline, without a defined monitoring schedule, and without understanding of what their body is doing biochemically as the medication takes effect. The weight may be moving in the right direction. But liver enzymes, kidney function, lean mass, lipids, and fasting insulin — the markers that tell a complete metabolic story — are rarely reviewed.

This matters because GLP-1 therapy is operating continuously in the body across multiple organ systems. The side effects that carry real long-term risk — hepatic enzyme elevation during rapid fat mobilization, kidney stress from GI-related dehydration, lean mass loss from inadequate protein intake, and pancreatic enzyme shifts — are often biochemically present weeks before symptoms emerge. By the time a patient feels something is wrong, the problem has often been developing for months.

Our clinical framework is built around the principle that GLP-1 therapy should be monitored like the chronic intervention it is. That means:

• Comprehensive pre-treatment metabolic labs before any prescription is written
• Structured follow-up at 3, 6, and 12 months with defined panels
• Body composition tracking that goes beyond weight to distinguish fat loss from lean mass loss
• Personalized clinical interpretation — because a lipase reading or an ALT shift means something different depending on your baseline, your rate of weight loss, and your comorbidities

We also recognize that for many patients, the most important question before starting GLP-1 therapy is the most basic one: Am I actually a good candidate for this, and what does my metabolic picture look like right now? That assessment — grounded in lab data and clinical history, not a brief telehealth questionnaire — is where responsible GLP-1 care begins.

Take the first step with Meto

If you are considering GLP-1 therapy or are currently on semaglutide or tirzepatide without proper baseline labs and monitoring in place, Meto's clinical team can help.

→ Get a GLP-1 Eligibility Assessment through Meto

Our intake process includes a full review of your metabolic health history, identification of any contraindications, and a personalized clinical plan — not a generic protocol. If GLP-1 therapy is appropriate for you, you will know exactly what your starting metabolic baseline looks like and what markers we will be tracking together.

You can also order your comprehensive metabolic lab panel directly before your first consultation.

This article is intended for educational purposes. It does not constitute medical advice. Consult a qualified healthcare provider before starting, stopping, or modifying any medical treatment.

Related reading on Meto:

• 10 Biomarkers to Track on GLP-1 Medications
• 5 GLP-1 Side Effects Lab Tests Can Catch Early
• Fasting Insulin: What It Tells You About Metabolic Health
• Wegovy Timeline: Month-by-Month Results Explained
• Meto's Comprehensive Metabolic Panel